人凝血酶原复合物临床应用研究进展

<正>凝血酶原复合物(PCC)的制备工艺目前国内外基本相同,都是以新鲜冰冻血浆(FFP)为起始原料,经DEAE A-50凝胶批式吸附(1次或者2次),超滤配制,冷冻干燥,并在制备过程中采用有机溶剂/去污剂(Solvent/Detergent,S/D)灭活脂包膜病毒(如HIV等)〔1〕,干热灭活法(如100℃/30 min,蒸汽60℃/10h)灭活非脂包膜病毒(如PPV,HCV等)〔2〕。成品为冻干粉针剂,运输、贮存、用药方便,病毒安全性高。随着血浆分离技术的不断提高,单

Research progress on clinical application of prothrombin complex concentrate

Prothrombin complex concentrate （PCC）, rich in vitamin K-dependent coagulation factors, is primarily used for treatment of bleeding caused by congenital or acquired vitamin K-dependent coagulation factor deficiency. Its main indications include Hemophilia B, liver disease and reversal of oral anticoagulation. The advantages of PCC are fast, efficient, safe, which is incomparable by fresh frozen plasma. Although there is a certain risk of thrombotic complications, it can be reduced to the lowest if cautious administration according to the clinical representation of patients. Therefore, PCC is effective and safe in supplying vitamin K-dependent coagulations factors, curing liver disease and reversal of oral anticoagulation.